Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model

Yeon Sook Lee, Jung Min Han, Taehee Kang, Young In Park, Hwan Mook Kim, Sunghoon Kim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalMolecules and Cells
Volume21
Issue number2
Publication statusPublished - 2006 Apr 30

Fingerprint

Paclitaxel
Human Activities
Cytokines
Neoplasms
Heterografts
Growth
Transfer RNA
Tumor Burden
Stomach Neoplasms
Lung Neoplasms
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cell Biology

Cite this

Lee, Y. S., Han, J. M., Kang, T., Park, Y. I., Kim, H. M., & Kim, S. (2006). Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model. Molecules and Cells, 21(2), 213-217.
Lee, Yeon Sook ; Han, Jung Min ; Kang, Taehee ; Park, Young In ; Kim, Hwan Mook ; Kim, Sunghoon. / Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model. In: Molecules and Cells. 2006 ; Vol. 21, No. 2. pp. 213-217.
@article{fb98ce4c61494cfd8f884af26f8c99a1,
title = "Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model",
abstract = "Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84{\%} and 94{\%} by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54{\%} (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.",
author = "Lee, {Yeon Sook} and Han, {Jung Min} and Taehee Kang and Park, {Young In} and Kim, {Hwan Mook} and Sunghoon Kim",
year = "2006",
month = "4",
day = "30",
language = "English",
volume = "21",
pages = "213--217",
journal = "Molecules and Cells",
issn = "1016-8478",
publisher = "Korean Society for Molecular and Cellular Biology",
number = "2",

}

Lee, YS, Han, JM, Kang, T, Park, YI, Kim, HM & Kim, S 2006, 'Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model', Molecules and Cells, vol. 21, no. 2, pp. 213-217.

Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model. / Lee, Yeon Sook; Han, Jung Min; Kang, Taehee; Park, Young In; Kim, Hwan Mook; Kim, Sunghoon.

In: Molecules and Cells, Vol. 21, No. 2, 30.04.2006, p. 213-217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model

AU - Lee, Yeon Sook

AU - Han, Jung Min

AU - Kang, Taehee

AU - Park, Young In

AU - Kim, Hwan Mook

AU - Kim, Sunghoon

PY - 2006/4/30

Y1 - 2006/4/30

N2 - Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.

AB - Although AIMP1 (previously known as p43) is one of three auxiliary proteins bound to a macromolecular aminoacyl tRNA complex, it is also secreted as a cytokine controlling both angiogenesis and immune responses. Here we show that systemically administered purified recombinant human AIMP1 had anti-tumor activity in mouse xenograft models. In Meth A-bearing Balb/c mice, tumor volume increased about 28 fold in the vehicle treatment group, while an increase of about 16.7 fold was observed in the AIMP1-treated group. We also evaluated the anti-tumor activity of AIMP1 in combination with a sub-clinical dose of the cytotoxic anti-tumor drug, paclitaxel. The growth of NUGC-3 human stomach cancer cells was suppressed by 84% and 94% by the combinations of 5 mg/kg paclitaxel + 25 mg/kg AIMP1 (p = 0.03), and 5 mg/kg paclitaxel + 50 mg/kg AIMP1 (p = 0.02), respectively, while 5 mg/kg paclitaxel alone suppressed growth by only 54% (p = 0.02). A similar cooperative effect of AIMP1 and paclitaxel was observed in a lung cancer xenograft model. These results suggest that AIMP1 may be useful as a novel anti-tumor agent.

UR - http://www.scopus.com/inward/record.url?scp=33646584134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646584134&partnerID=8YFLogxK

M3 - Article

C2 - 16682815

AN - SCOPUS:33646584134

VL - 21

SP - 213

EP - 217

JO - Molecules and Cells

JF - Molecules and Cells

SN - 1016-8478

IS - 2

ER -

Lee YS, Han JM, Kang T, Park YI, Kim HM, Kim S. Antitumor activity of the novel human cytokine AIMP1 in an in vivo tumor model. Molecules and Cells. 2006 Apr 30;21(2):213-217.